NorthStar Medical Radioisotopes Announces Presentations at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

BELOIT, Wis., June 10, 2021 – NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging, today announced presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, being held in a virtual format from June 11 −15, 2021. NorthStar will host an event in conjunction with the SNMMI Value Initiative, “Accelerating the Future of Nuclear Medicine: Advances in Radioisotope and Therapeutic Technologies.” In addition, NorthStar President and Chief Executive Officer Stephen Merrick is part of a CEO Summit and Panel discussion, “The Potential, Promise and Future of Therapeutics.” Details on the events are listed below.

Friday, June 11, 2021 – 6:15 pm ET

CEO Summit and Panel Discussion − The Potential, Promise and Future of Therapeutics
Stephen Merrick will participate in this informative panel discussion with CEOs and industry leaders, as well as leading SNMMI medical and scientific experts in nuclear medicine, molecular imaging, and radiopharmaceutical therapy. They will speak about system-wide strategies to ensure that patients have access to the best therapeutic outcomes and that potentially ground-breaking new therapies move from bench to bedside more efficiently.

Saturday, June 12, 2021 – 9:15 – 10:15 am ET

NorthStar SNMMI Value Initiative Event – Accelerating the Future of Nuclear Medicine: Advances in Radioisotope and Therapeutic Technologies
NorthStar senior executives, industry leaders and customers will discuss NorthStar’s pioneering USA-Made Mo-99, advancements in first-of-kind electron accelerators, and plans for strategic collaborations to produce and commercialize game-changing radiotherapeutics.

Invited guest speakers include:
• Shaemus Gleason, Executive VP, U.S. Operations, Clarity Pharmaceuticals
• Joseph Foo RPh., BCNP, Director of Pharmacy, Patient Care Infusion, Tempe, AZ
• Oliver Sartor, MD, Professor of Medicine, Medical Director, Tulane Cancer Center, C. E. and Bernadine Laborde Professor of Cancer Research

NorthStar invites participants at this year’s SNMMI 2021 virtual Annual Meeting to attend the presentations above and to visit its virtual Commercial Exhibit Booth. For information, please visit: SNMMI 2021 Virtual Annual Meeting.

About NorthStar Medical Radioisotopes, LLC (NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage nuclear medicine company that develops, produces, and manufactures reliable and environmentally-friendly diagnostic and therapeutic radiopharmaceuticals. Its first FDA-approved diagnostic imaging product is technetium-99m (Tc-99m), which is used in 40,000 patient imaging studies per day in the United States as standard of care to assess extent and severity of heart disease and cancer. Tc-99m is generated by NorthStar’s novel RadioGenix® System (technetium Tc 99m generator) that uses U.S.-produced, non-uranium based molybdenum-99 (Mo-99) as its source material. The Company is executing a well-defined plan to consistently increase the scale of Mo-99 production and to continuously improve efficiencies to meet anticipated increased demand. Therapeutic radioisotopes are increasingly important cancer treatment options, and NorthStar is developing commercial-scale production technologies to meet high demand for their use in ongoing clinical trials by multiple pharmaceutical companies. In addition, the Company is advancing a portfolio of other radiopharmaceuticals for use in therapeutic and diagnostic applications. For more information, visit: www.northstarnm.com.

For NorthStar Medical Radioisotopes, LLC
Corporate:
Lisa Holst
Vice President Sales and Marketing
678-471-9027
[email protected]

Investor Relations:
Paul Estrem
Executive Vice President and Chief Financial Officer
608-987-8318
[email protected]

Media:
Priscilla Harlan
781-799-7917
[email protected]